RT Journal Article
SR Electronic
T1 The ratio of cytotoxic lymphocytes to M2-like macrophages is prognostic in immunogenic tumors
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.03.24.436814
DO 10.1101/2021.03.24.436814
A1 Artur Mezheyeuski
A1 Max Backman
A1 Johanna Mattsson
A1 Alfonso Martín-Bernabé
A1 Chatarina Larsson
A1 Ina Hrynchyk
A1 Klara Hammarström
A1 Simon Ström
A1 Joakim Ekström
A1 Siarhei Mauchanski
A1 Salome Khelashvili
A1 Margrét Agnarsdóttir
A1 Per-Henrik Edqvist
A1 Jutta Huvila
A1 Ulrika Segersten
A1 Per-Uno Malmström
A1 Johan Botling
A1 Björn Nodin
A1 Charlotta Hedner
A1 David Borg
A1 Jenny Brändstedt
A1 Hanna Sartor
A1 Karin Leandersson
A1 Bengt Glimelius
A1 Anna Portyanko
A1 Fredrik Ponten
A1 Karin Jirström
A1 Patrick Micke
A1 Tobias Sjöblom
YR 2021
UL http://biorxiv.org/content/early/2021/03/24/2021.03.24.436814.abstract
AB Immune cells in the microenvironment shape tumor development and progression. The prognostic value of T-cell-based immune scores exceeds those of clinical parameters in colon cancer, but reflects only a part of the anti-tumor immune response. Here, we assessed 15 distinct immune cell classes and identified a simple prognostic signature based on pro- and anti-tumoral immune cells in the tumor microenvironment. The ratio of cytotoxic lymphocytes to tumor supportive macrophages predicted survival better than the state-of-art immune score in colon cancer and had the highest relative contribution to survival prediction when compared to established clinical parameters. This signature was prognostic also in other cancers with high mutation burden, such as those of the lung, bladder, esophagus, and melanomas, supporting broad clinical applicability.One Sentence Summary The CD8/M2 ratio in tumor tissue defines prognosis in immunogenic cancersCompeting Interest StatementA.M and T.S are co-inventors on a provisional patent application P42105124SE00 Novel biomarker, regarding the novel method for the prognosis of survival time of a subject diagnosed with a cancer described herein. No conflicts of interest were disclosed by the other authors.